摘要
目的探讨异基因造血干细胞移植(Allo-HSCT)治疗B细胞性急性淋巴细胞白血病(B-ALL)的疗效。方法外周血Allo-HSCT治疗B-ALL 15例。预处理方案:6例为改良马利兰(BU)联合环磷酰胺(CY),9例为环磷酰胺/全身照射(TBI)。预防急性移植物抗宿主病(GVHD)采用环孢霉素A、短程甲氨喋呤及霉酚酸酯(骁悉)。结果输注单个核细胞5.36-12.30×108/kg,中性粒细胞大于0.5×109/L的为10-15d。血小板大于20×109/L的为11-16d。6例(40.0%)发生急性GVHD,6例(40.0%)发生慢性GVHD,皆为广泛性。中位随访时间14个月(2.5-65个月),9例患者无病生存。结论 Allo-HSCT可以作为治疗成人B-ALL的有效手段。
Objective To explore the efficacy of treating B cell acute lymphocytic leukemia（B- ALL） with allogeneic hematopoietic stem cell transplantation（HSCT）. Methods Fifteen patients with B-ALL received HSCT from peripheral blood, which was preconditioned with busulfan（BU） and cyclophosphamide（CY） in six patients, and with TBI and cyclophosphamide（CY） in nine patients. The prophylaxis regimen for graft versus host disease （GVHD） consisted of cyclosporine A （CSA）, methotre xate（MTX） and mycophenolate mofetil（MMF）. Results The patients received mononuclear cells 5.36-12. 30X 108/kg,The time of ANC（〉0. 5 109/L） was 10-15 days,and that of Plt（〉20. 0×10^9/ L） was 11-16 days. Acute GVHD grade occurred in 6 （40. 0 % ） patients, extensive chronic GVHD occurred in 6 （40.0%）patients. Nine patients were alive and well during following-up for 2.5-65 months. Conclusion Allogeneic stem cell transplant appears to be effective for the treatment of B-ALL.
出处
《江苏医药》
CAS
CSCD
北大核心
2012年第21期2543-2546,共4页
Jiangsu Medical Journal
关键词
造血干细胞移植
急性淋巴细胞白血病
Hematopoietic stem cell transplantation
Acute lymphocyti leukemia
